<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00772551</url>
  </required_header>
  <id_info>
    <org_study_id>SSAT027</org_study_id>
    <nct_id>NCT00772551</nct_id>
  </id_info>
  <brief_title>Raltegravir and Ezetimibe PK Study</brief_title>
  <official_title>Evaluation of the Pharmacokinetics and Safety of Raltegravir and Ezetimibe When Co-administered to Male and Female Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St Stephens Aids Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St Stephens Aids Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the pharmacokinetics and safety of raltegravir and ezetimibe when
      co-administered to male and female healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Steady state plasma concentrations of raltegravir and ezetimibe when given alone and in combination</measure>
    <time_frame>41 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of raltegravir and ezetimibe co-administration. Association between genetic polymorphisms in drug disposition genes and drug exposure.</measure>
    <time_frame>41 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir and ezetimibe</intervention_name>
    <description>Group 1: raltegravir 400 mg orally twice daily for 10 days followed by 10 days of raltegravir 400 mg twice daily and ezetimibe 10 mg orally once daily for 10 days followed by a 10 days wash out period and ezetimibe 10 mg once daily for 10 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe and raltegravir</intervention_name>
    <description>Group2: ezetimibe 10 mg orally once daily for 10 days followed by ezetimibe 10 mg and raltegravir 400 mg orally twice daily for 10 days followed by a 10 days wash out period and raltegravir 400 mg twice daily for 10 days</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The ability to understand and sign a written informed consent form, prior to
             participation in any screening procedures and must be willing to comply with all study
             requirements

          -  Male or non-pregnant, non-lactating females

          -  Between 18 to 65 years, inclusive

          -  Body Mass Index (BMI) of 18 to 35 kg/m2, inclusive.

          -  Women of childbearing potential (WOCBP) must be using an adequate method of
             contraception to avoid pregnancy throughout the study and for a period of at least 1
             month after the study

        Exclusion Criteria:

          -  Any significant acute or chronic medical illness

          -  Evidence of organ dysfunction or any clinically significant deviation from normal in
             physical examination, vital signs, ECG or clinical laboratory determinations

          -  Positive blood screen for hepatitis B and/or C antibodies

          -  Positive blood screen for HIV-1 and 2 antibodies

          -  Current or recent (within 3 months) gastrointestinal disease

          -  Clinically relevant alcohol or drug use (positive urine drug screen) or history of
             alcohol or drug use considered by the Investigator to be sufficient to hinder
             compliance with treatment, follow-up procedures or evaluation of adverse events.
             Smoking is permitted, but tobacco intake should remain consistent throughout the study

          -  Exposure to any investigational drug or placebo within 4 weeks of first dose of study
             drug

          -  Consumption of grapefruit, or Seville oranges or any grapefruit or Seville orange
             containing product within one week of first dose of study drug and for the duration of
             the study

          -  Use of any other drugs, including over-the-counter medications and herbal
             preparations, within two weeks prior to first dose of study drug, unless
             approved/prescribed by the Principal Investigator as known not to interact with study
             drugs.

          -  Females of childbearing potential without the use of effective non-hormonal birth
             control methods, or not willing to continue practising these birth control methods for
             at least 30 days after the end of the treatment period

          -  Previous allergy to any of the constituents of the pharmaceuticals administered in
             this trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marta Boffito</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Stephen's AIDS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chelsea and Westminster Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SW10 9NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2008</study_first_submitted>
  <study_first_submitted_qc>October 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2008</study_first_posted>
  <last_update_submitted>August 13, 2010</last_update_submitted>
  <last_update_submitted_qc>August 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr Marta Boffito</name_title>
    <organization>St Stephen's AIDS Trust</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 6, 2011</submitted>
    <returned>May 2, 2011</returned>
    <submitted>June 6, 2012</submitted>
    <returned>July 6, 2012</returned>
    <submitted>June 26, 2017</submitted>
    <returned>January 30, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

